| Index | — | P/E | — | EPS (ttm) | -0.99 | Insider Own | — | Shs Outstand | 37.49M | Perf Week | -2.59% |
| Market Cap | 1.06B | Forward P/E | 12.94 | EPS next Y | 2.18 | Insider Trans | 0.01% | Shs Float | 28.93M | Perf Month | -7.48% |
| Enterprise Value | 1.27B | PEG | — | EPS next Q | 0.17 | Short Float | 25.84% | Perf Quarter | -29.20% | ||
| Income | -37.00M | P/S | 3.83 | EPS this Y | -222.91% | Short Ratio | 12.99 | Perf Half Y | -29.85% | ||
| Sales | 276.00M | P/B | 70.48 | EPS next Y | — | ROA | -8.93% | Short Interest | 7.47M | Perf YTD | -42.45% |
| Book/sh | 0.40 | P/C | 12.59 | EPS next 5Y | — | ROE | -103.86% | 52W High | 54.85 -48.59% | Perf Year | -24.92% |
| Cash/sh | 2.24 | P/FCF | — | EPS past 3/5Y | — | ROIC | 1.81% | 52W Low | 26.96 4.60% | Perf 3Y | 104.64% |
| Dividend Est. | — | EV/EBITDA | 106.01 | Sales past 3/5Y | 45.12% 40.89% | Gross Margin | 73.28% | Volatility | 4.41% 4.67% | Perf 5Y | 191.02% |
| Dividend TTM | — | EV/Sales | 4.61 | EPS Y/Y TTM | — | Oper. Margin | 2.07% | ATR (14) | 1.36 | Perf 10Y | 843.14% |
| Dividend Ex-Date | — | Quick Ratio | 2.08 | Sales Y/Y TTM | 21.05% | Profit Margin | -13.51% | RSI (14) | 38.35 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.24 | EPS Q/Q | -428.57% | SMA20 | -2.06% | Beta | 0.15 | Target Price | 66.50 |
| Payout | 0.00% | Debt/Eq | 19.93 | Sales Q/Q | 10.94% | SMA50 | -13.51% | Rel Volume | 1.28 | Prev Close | 28.24 |
| Employees | 373 | LT Debt/Eq | 19.93 | Earnings | Nov 09 | SMA200 | -26.27% | Avg Volume | 580.99K | Price | 28.20 |
| IPO Date | Sep 28, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -157.34% 0.44% | Net Debt/EBITDA | 17.92 | Volume | 742,123 | Change | -0.14% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Initiated | Leerink | Outperform | $45 |
| May-13-26 | Reiterated | Cantor Fitzgerald | Overweight | $94 → $88 |
| Mar-18-26 | Reiterated | BTIG | Buy | $63 |
| Mar-04-26 | Reiterated | HC Wainwright & Co. | Buy | $64 → $70 |
| Nov-11-25 | Reiterated | Cantor Fitzgerald | $76 → $94 | |
| Sep-29-25 | Reiterated | Lake Street | Buy | $55 → $70 |
| Sep-23-25 | Reiterated | Craig-Hallum | Buy | $45 → $64 |
| Aug-13-25 | Reiterated | HC Wainwright & Co. | Buy | $64 |
| Jul-11-25 | Initiated | Cantor Fitzgerald amid path to growth | Overweight | $76 |
| Oct-18-24 | Reiterated | B.Riley Financial | Buy | $73 |
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 276 | 272 | 200 | 130 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 73 | 68 | 49 | 40 | — | — | — | — | — | |
| Gross Profit | 202 | 204 | 150 | 91 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 139 | 153 | 0 | 0 | — | — | — | — | — | |
| Research and Development | 20 | 13 | 12 | 7 | — | — | — | — | — | |
| Other Operating Expense | 37 | 0 | 130 | 83 | — | — | — | — | — | |
| Operating Income | 6 | 39 | 9 | 0 | — | — | — | — | — | |
| Interest Expense | 22 | 24 | 23 | 21 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -16 | -16 | -3 | -3 | — | — | — | — | — | |
| Net Income Before Taxes | -34 | -2 | -17 | -24 | — | — | — | — | — | |
| Income Taxes | 4 | 3 | 0 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -37 | -5 | -17 | -24 | — | — | — | — | — | |
| Net Income From Continuing Operations | -37 | -5 | -17 | -24 | — | — | — | — | — | |
| Net Income | -37 | -5 | -17 | -24 | — | — | — | — | — | |
| EPS (Recurring) | -0.99 | -0.14 | -0.49 | -0.75 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.99 | -0.14 | -0.49 | -0.75 | — | — | — | — | — | |
| EPS (Diluted) | -0.99 | -0.14 | -0.49 | -0.75 | — | — | — | — | — | |
| EBITDA | 12 | 42 | 24 | 13 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.78 | 6.67 | 6.04 | 2.84 | — | — | — | — | — | |
| Gross Margin | 73.19 | 75.00 | 75.00 | 70.00 | — | — | — | — | — | |
| Operating Margin | 2.17 | 14.34 | 4.50 | 0.00 | — | — | — | — | — | |
| Net Margin | -13.41 | -1.84 | -8.50 | -18.46 | — | — | — | — | — | |
| Shares Outstanding | 37 | 37 | 36 | 33 | — | — | — | — | — | |
| Market Capitalization | 1,043 | 1,813 | 1,208 | 370 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER | Aug 14 '26 | Option Exercise | 35.96 | 11,250 | 404,550 | 11,250 | Aug 17 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER | Aug 14 '26 | Sale | 40.00 | 11,250 | 450,000 | 0 | Aug 17 |
| Graves Adrienne L | Director | May 18 '26 | Buy | 31.07 | 1,000 | 31,070 | 1,000 | May 19 |
| SILVERNAIL LAUREN P | Director | May 18 '26 | Buy | 31.00 | 1,000 | 31,000 | 1,000 | May 19 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER | May 14 '26 | Buy | 30.20 | 10,000 | 302,000 | 2,996,130 | May 15 |
| BOLL ANDREW R. | PRESIDENT AND CFO | May 14 '26 | Buy | 29.90 | 3,500 | 104,650 | 814,679 | May 15 |
| Opaleye Management Inc. | 10% Owner | Mar 04 '26 | Sale | 39.67 | 138,263 | 5,485,183 | 59,428 | Mar 05 |
| Opaleye Management Inc. | 10% Owner | Mar 03 '26 | Sale | 39.15 | 60,309 | 2,361,242 | 63,691 | Mar 05 |
| Opaleye Management Inc. | 10% Owner | Feb 27 '26 | Sale | 54.18 | 5,000 | 270,900 | 65,000 | Mar 03 |
| Opaleye Management Inc. | 10% Owner | Jan 06 '26 | Sale | 53.35 | 20,000 | 1,066,914 | 70,000 | Jan 08 |
| BOLL ANDREW R. | PRESIDENT AND CFO | Dec 12 '25 | Option Exercise | 3.95 | 60,000 | 237,000 | 837,844 | Dec 16 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER | Dec 12 '25 | Option Exercise | 3.95 | 180,000 | 711,000 | 3,066,124 | Dec 16 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER | Jul 21 '25 | Option Exercise | 7.87 | 600,000 | 4,722,000 | 3,199,462 | Jul 23 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER | Jul 31 '15 | Option Exercise | 7.87 | 600,000 | 4,722,000 | 0 | Jul 23 |
| Opaleye Management Inc. | 10% Owner | Jun 10 '25 | Sale | 30.80 | 15,000 | 462,033 | 90,000 | Jun 11 |